Cargando…

A New Paradigm of Cardiovascular Risk Factor Modification

Atherosclerotic cardiovascular diseases (CVDs) are the leading cause of death and disability in the United States. While multiple studies have demonstrated that modification of atherosclerotic cardiovascular risk factors (CVRFs) significantly reduces morbidity and mortality rates, clinical control o...

Descripción completa

Detalles Bibliográficos
Autores principales: Firdaus, Muhammad, Asbury, Jeffery M, Reynolds, Dwight W
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993940/
https://www.ncbi.nlm.nih.gov/pubmed/17315396
_version_ 1782135451036942336
author Firdaus, Muhammad
Asbury, Jeffery M
Reynolds, Dwight W
author_facet Firdaus, Muhammad
Asbury, Jeffery M
Reynolds, Dwight W
author_sort Firdaus, Muhammad
collection PubMed
description Atherosclerotic cardiovascular diseases (CVDs) are the leading cause of death and disability in the United States. While multiple studies have demonstrated that modification of atherosclerotic cardiovascular risk factors (CVRFs) significantly reduces morbidity and mortality rates, clinical control of CVDs and CVRFs remains poor. By 2010, the American Heart Association seeks to reduce coronary heart disease, stroke, and risk by 25%. To meet this goal, clinical practitioners must establish new treatment paradigms for CVDs and CVRFs. This paper discusses one such treatment model – a comprehensive atherosclerosis program run by physician extenders (under physician supervision), which incorporates evidence-based CVD and CVRF interventions to achieve treatment goals.
format Text
id pubmed-1993940
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-19939402008-03-06 A New Paradigm of Cardiovascular Risk Factor Modification Firdaus, Muhammad Asbury, Jeffery M Reynolds, Dwight W Vasc Health Risk Manag Commentary Atherosclerotic cardiovascular diseases (CVDs) are the leading cause of death and disability in the United States. While multiple studies have demonstrated that modification of atherosclerotic cardiovascular risk factors (CVRFs) significantly reduces morbidity and mortality rates, clinical control of CVDs and CVRFs remains poor. By 2010, the American Heart Association seeks to reduce coronary heart disease, stroke, and risk by 25%. To meet this goal, clinical practitioners must establish new treatment paradigms for CVDs and CVRFs. This paper discusses one such treatment model – a comprehensive atherosclerosis program run by physician extenders (under physician supervision), which incorporates evidence-based CVD and CVRF interventions to achieve treatment goals. Dove Medical Press 2005-06 2005-06 /pmc/articles/PMC1993940/ /pubmed/17315396 Text en © 2005 Dove Medical Press Limited. All rights reserved
spellingShingle Commentary
Firdaus, Muhammad
Asbury, Jeffery M
Reynolds, Dwight W
A New Paradigm of Cardiovascular Risk Factor Modification
title A New Paradigm of Cardiovascular Risk Factor Modification
title_full A New Paradigm of Cardiovascular Risk Factor Modification
title_fullStr A New Paradigm of Cardiovascular Risk Factor Modification
title_full_unstemmed A New Paradigm of Cardiovascular Risk Factor Modification
title_short A New Paradigm of Cardiovascular Risk Factor Modification
title_sort new paradigm of cardiovascular risk factor modification
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993940/
https://www.ncbi.nlm.nih.gov/pubmed/17315396
work_keys_str_mv AT firdausmuhammad anewparadigmofcardiovascularriskfactormodification
AT asburyjefferym anewparadigmofcardiovascularriskfactormodification
AT reynoldsdwightw anewparadigmofcardiovascularriskfactormodification
AT firdausmuhammad newparadigmofcardiovascularriskfactormodification
AT asburyjefferym newparadigmofcardiovascularriskfactormodification
AT reynoldsdwightw newparadigmofcardiovascularriskfactormodification